Distinct presynaptic regulation of dopamine release through NMDA receptors in striosome- and matrix-enriched areas of the rat striatum.
Striosome- and matrix-enriched striatal zones were defined in coronal and sagittal brain sections of the rat, on the basis of 3H-naloxone binding to mu-opiate receptors (a striosome-specific marker). Then, using a new in vitro microsuperfusion device, the NMDA (50 microM)-evoked release of newly synthesized 3H-dopamine (3H-DA) was examined in these four striatal areas under Mg(2+)-free conditions. The amplitudes of the responses were different in striosomal (171 +/- 6% and 161 +/- 5% of the spontaneous release) than in matrix areas (223 +/- 6% and 248 +/- 12%), even when glycine (1 or 100 microM) was coapplied (in the presence of 1 microM strychnine). In the four areas, the NMDA-evoked release of 3H-DA was blocked completely by Mg2+ (1 mM) or (+)-5-methyl-10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5,10-imine maleate (MK-801; 1 microM) and almost totally abolished by kynurenate (100 microM). Because the tetrodotoxin (TTX)-resistant NMDA-evoked release of 3H-DA was similar in striosome- (148 +/- 5% and 152 +/- 6%) or matrix-enriched (161 +/- 5% and 156 +/- 7%) areas, the indirect (TTX-sensitive) component of NMDA-evoked responses, which involves striatal neurons and/or afferent fibers, seems more important in the matrix- than in the striosome-enriched areas. The modulation of DA release by cortical glutamate and/or aspartate-containing inputs through NMDA receptors in the matrix appears thus to be partly distinct from that observed in the striosomes, providing some functional basis for the histochemical striatal heterogeneity.
Krebs
M O
MO
Chaire de Neuropharmacologie, INSERM U114, Collège de France, Paris.
Trovero
F
F
Desban
M
M
Gauchy
C
C
Glowinski
J
J
Kemel
M L
ML
D000818:Animals; D001345:Autoradiography; D003342:Corpus Striatum / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D004298:Dopamine / Q000378:metabolism*; D007700:Kinetics; D008297:Male; D016202:N-Methylaspartate / Q000494:pharmacology*; D009270:Naloxone / Q000378:metabolism; D009411:Nerve Endings / Q000187:drug effects / Q000502:physiology; D051381:Rats; D011919:Rats, Inbred Strains; D016194:Receptors, N-Methyl-D-Aspartate / Q000187:drug effects / Q000502:physiology*; D011957:Receptors, Opioid / Q000378:metabolism; D017450:Receptors, Opioid, mu; D013569:Synapses / Q000187:drug effects / Q000502:physiology*; D014316:Tritium
D016194:Receptors, N-Methyl-D-Aspartate; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D014316:Tritium; D009270:Naloxone; D016202:N-Methylaspartate; D004298:Dopamine